Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 200,000 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 200,000 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $80.57, for a total value of $16,114,000.00. Following the transaction, the chief executive officer directly owned 809,631 shares in the company, valued at $65,231,969.67. This represents a 19.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

TEM stock traded down $2.52 during trading on Friday, reaching $77.84. 9,310,212 shares of the company were exchanged, compared to its average volume of 7,226,184. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The stock’s 50 day moving average price is $57.19 and its 200 day moving average price is $52.90. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The company has a market cap of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period last year, the firm earned ($0.22) EPS. As a group, analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TEM shares. Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and raised their price target for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Guggenheim raised their target price on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. UBS Group began coverage on shares of Tempus AI in a report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target on the stock. HC Wainwright increased their price target on shares of Tempus AI from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Finally, Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Eleven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $69.33.

Institutional Trading of Tempus AI

A number of hedge funds have recently added to or reduced their stakes in the business. EMC Capital Management purchased a new stake in Tempus AI in the second quarter valued at approximately $29,000. Whittier Trust Co. boosted its holdings in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the last quarter. CoreCap Advisors LLC boosted its holdings in shares of Tempus AI by 293.4% in the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after purchasing an additional 760 shares during the last quarter. Global Assets Advisory LLC purchased a new stake in shares of Tempus AI during the 1st quarter valued at $46,000. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in shares of Tempus AI during the 4th quarter valued at $70,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.